Other Events ·
Oncotelic Therapeutics presents PDAOAI platform and HCC research at Drug Discovery 2026
OTLCOncotelic Therapeutics, Inc.
On October 7 and 8, 2026, Oncotelic Therapeutics representatives presented information regarding its PDAOAI platform and hepatocellular carcinoma (HCC) research at the Drug Discovery 2026 conference in Burlingame, California. The presentations detailed the platform's search capabilities and a four-gene mTOR-related signature associated with overall survival in exploratory analyses. The company also described an initiative inviting researchers to propose therapeutic projects using PDAOAI for potential startup funding. Oncotelic Therapeutics operates as a biotechnology company focused on drug discovery platforms and oncology research.